Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy
This study will investigate the effects of rosiglitazone, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. The primary purpose of the study is to determine whether treatment with an insulin-sensitizing medication will improve the heart's ability to metabolize glucose (sugar).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Rosiglitazone therapy
Ages Eligible For Study:
- Diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-II congestive heart failure - History of Stage C-D heart failure with EF ? 40% during the course of the disease - Treatment with a stable comprehensive heart failure regimen for at least 3 months (including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless intolerant) - Age > 18 yrs